FDA Approval ≠ Commercial Differentiation
Two evidence needs. One integrated development strategy.
Evidence for FDA Approval
- Established clinical endpoints
- Evidence of safety and effectiveness
- Appropriate regulatory pathway
Potential result: Approval
Evidence for Commercial Value
- Meaningful patient outcomes
- Treatment timing and positioning
- Evidence of clinical differentiation
Potential result: Stronger licensing and adoption case
A drug may be approvable without demonstrating why physicians, payers, or partners should choose it.
Two Patients. Two Diseases. One Development Challenge.
Imagine two patients.
The first is a 70-year-old woman whose husband notices she has started repeating questions, forgetting appointments, and struggling with everyday decisions. For months, her family hopes the changes are simply part of aging.
The second is an 18-year-old who experiences a seizure just as adulthood is beginning. College, driving, employment, and independence suddenly become uncertain.
These are illustrative patients, not predictions of how either disease will unfold. But their journeys raise the same question for biotechnology developers:
Are we generating evidence only to establish that a drug works—or also to explain when, for whom, and why it can make a meaningful difference?
This is not a criticism of physicians working with the evidence available to them. Nor is it a call to make every clinical trial larger and more expensive. It is a question of capital allocation: will a development program establish the clinical differentiation needed for licensing, reimbursement, and adoption, or only what is necessary for regulatory approval?
Alzheimer's Disease: When the Patient Journey Begins Before Diagnosis
For many families, the Alzheimer's journey begins quietly. A spouse notices repeated questions. An adult child sees forgotten conversations. A familiar daily task becomes unexpectedly difficult.
Early symptoms may be dismissed, sometimes because the family fears what a diagnosis could mean. Eventually, a primary care assessment leads to cognitive testing and, when appropriate, specialist evaluation and biomarker confirmation. The patient may be diagnosed with mild cognitive impairment (MCI) due to Alzheimer's disease or Alzheimer's dementia. Dementia and Alzheimer's are not interchangeable terms: dementia describes a syndrome; Alzheimer's is one possible underlying disease.
By the time a diagnosis is established, changes may have been occurring for years. Some individuals still manage most daily activities independently. Others already require considerable assistance. Neither outcome follows a universal timeline.
The development question: how early is early enough?
Disease-modifying anti-amyloid therapies such as lecanemab and donanemab have demonstrated slowing of clinical decline in selected patients with early symptomatic Alzheimer's disease. Their use involves eligibility requirements, safety risks, and monitoring burdens; they are not cures. Meanwhile, investigational programs are exploring amyloid, tau, neuroinflammation, neuroprotection, and other mechanisms.
The FDA's 2024 draft guidance on early Alzheimer's explicitly addresses intervention before overt dementia and the difficult problem of measuring benefit in earlier stages. Prevention and preclinical studies are also under way. The industry is not ignoring early disease.
But a developer still must answer: Which patients should be identified, how early should treatment begin, and what evidence would show that earlier treatment preserves something meaningful?
MRI measures and blood or imaging biomarkers can strengthen understanding of mechanism and disease biology. They do not, by themselves, establish that a person can remain independent longer. Clinical relevance must be demonstrated.
What patients and caregivers hope to preserve
Return to our patient's household. Can she still manage her medications? Participate in family conversations? Prepare a meal safely? Make ordinary decisions? Remain involved in the life she knows?
Her husband may gradually take on transportation, appointments, finances, and personal care. Patient independence and caregiver experience matter, but those priorities do not always align perfectly. Alzheimer's trials already measure cognition and function, and caregiver outcomes have been studied. The opportunity is not to pretend they have been overlooked.
It is to ask whether specific, patient- and caregiver-defined milestones can be incorporated early enough in development to strengthen the eventual evidence of meaningful clinical benefit.
That might require validated secondary endpoints, thoughtful follow-up, or additional prospective evidence—not necessarily a new pivotal primary endpoint.
A potential licensing partner will want to know whether a proposed benefit is demonstrated, how durable it is, which patients experience it, and how it may influence real-world use. A compelling story is not a substitute for evidence.
Epilepsy: When Fewer Seizures May Still Mean Less Freedom
Now consider the 18-year-old. Following the first recognized seizure, emergency clinicians assess and stabilize the patient. Further evaluation may include history, imaging where indicated, EEG, and follow-up with a neurologist. Whether maintenance antiseizure therapy starts immediately depends on the clinical circumstances and recurrence risk; IV levetiracetam followed by oral levetiracetam is not an automatic first-seizure pathway.
For many people, established medicines—including affordable generics—control seizures effectively. Others continue to experience seizures, experience troublesome adverse effects, or require treatment adjustments. This is not evidence that generics are inferior; several established therapies provide excellent care.
But for a young adult, uncontrolled seizures can affect driving eligibility, independence, education, employment, relationships, and confidence. The family may unexpectedly become the transportation network and a source of continuous support.
The development question: is seizure reduction enough to differentiate?
In focal epilepsy, reduction in seizure frequency is an accepted and important efficacy measure. A 50% reduction can be medically significant. Yet a patient who continues to have unpredictable seizures may still face meaningful restrictions.
Sustained seizure freedom, when achieved with acceptable tolerability, can represent a different kind of benefit from seizure reduction alone. It can create opportunities for independence, although driving eligibility and other decisions depend on applicable rules and individual circumstances.
Seizure freedom is already assessed in epilepsy studies; it is not a newly discovered outcome. The development question is whether an investigational drug can establish a compelling position through durable seizure control, tolerability, suitable patient selection, and evidence relevant to its intended place in therapy.
Physicians already have multiple effective options, including lacosamide, brivaracetam, cenobamate, and other medicines. No single agent should be presumed best for every patient.
A new developer must make a credible case for why its therapy is meaningfully different.
The question of treatment timing
The International League Against Epilepsy defines drug-resistant epilepsy by failure of two appropriately chosen and adequately tried antiseizure medication regimens to achieve sustained seizure freedom. That definition helps identify when comprehensive specialist evaluation becomes important.
For developers, a separate question arises: Could a therapy create additional value in a defined population if used earlier in the treatment sequence? That is a hypothesis to test, not a conclusion to advertise.
Evidence from adjunctive trials in patients with inadequately controlled epilepsy cannot automatically establish first-line superiority. Earlier-use claims demand appropriate research.
But if the company never plans how to investigate treatment positioning, it may reach approval without the evidence needed to support the use it ultimately hopes to achieve.
An Efficient Approval Program Can Still Leave a Commercial Evidence Gap
Emerging biotech companies live within real constraints. Trial enrollment, cash runway, financing risk, and regulatory certainty matter. An established route to approval can be the rational first choice.
But the minimum evidence sufficient for approval may not be sufficient to establish commercial differentiation.
Imagine an epilepsy developer with a successful pivotal study. Its investigational drug meets the chosen endpoint and demonstrates a positive benefit-risk profile. That is an important scientific achievement. The company now seeks a licensing partner.
The partner's questions may be different from the pivotal study's questions: Which patients are most likely to receive it? Why would clinicians choose it over existing therapies? What does the evidence establish about durability, tolerability, meaningful patient outcomes, and its position in the treatment algorithm? Can payers see a defensible value proposition?
The same questions arise in Alzheimer's. A biomarker signal, imaging result, or change on a cognitive scale may be scientifically informative, but a potential partner must assess how the claimed benefits translate into patient selection, adoption, access, and a credible forecast.
When the evidence does not answer those questions, a partner may assign more uncertainty to the asset, propose additional work, or structure a transaction with more contingencies. That is not inevitable, and no particular licensing outcome can be guaranteed. It is a commercial risk created by unanswered development questions.
A company can reduce near-term spending through a narrow study program yet potentially leave more value unproven than it saves in development costs.
Patient-Focused Evidence Is a Strategic Investment, Not a Marketing Add-On
FDA patient-focused drug development guidance offers methods for identifying outcomes patients consider important and selecting fit-for-purpose clinical outcome assessments. These frameworks do not mean every life milestone belongs in the primary endpoint or that every company should finance a large comparative trial.
They do mean patient experience can inform a disciplined evidence strategy before a protocol is locked.
For Alzheimer's, that might mean prospective planning around the stage of disease, function, caregiver measures, and the clinical interpretation of biomarkers. For epilepsy, it might mean carefully defined seizure-freedom measures, durability, tolerability, and a credible later-stage plan to examine treatment positioning.
The best approach depends on the asset. Some questions must be answered prospectively during pivotal development. Others may be addressed through follow-up, registries, additional studies, or appropriate real-world evidence. None should be treated as automatically proven simply because the primary efficacy endpoint succeeds.
Five Questions for Biotech CEOs, Boards, and Investors
- What evidence is essential for approval? Protect regulatory rigor and avoid needless complexity.
- What benefit could truly differentiate the asset? Define it in terms of patients, appropriate treatment timing, and existing alternatives.
- What will licensing partners and payers need to believe? Identify the evidence behind adoption assumptions, pricing, access, and forecasts.
- Which questions must influence the trial design now? Separate evidence that cannot be recovered later from work that can be staged responsibly.
- What is the economic cost of the unanswered questions? Weigh near-term study savings against the uncertainty a partner or future commercial team may inherit.
The objective is not the largest evidence package. It is the most capital-efficient package that supports both regulatory success and a credible commercial proposition.
The Question Behind the Development Budget
Return to our two patients: the woman hoping to preserve familiar decisions and daily routines, and the young adult hoping to study, work, drive when eligible, and build an independent life.
Their experiences should never be reduced to a marketing story. They are a reminder of what treatment is intended to change—and of the questions clinical evidence must answer.
When boards review development budgets, they rightly scrutinize study cost, enrollment speed, regulatory milestones, and runway. They should also ask:
Are we spending millions to prove our drug works without adequately establishing why clinicians, payers, and licensing partners will choose it?
The cost of treatment is visible on a pharmacy claim. The cost of delayed independence can be distributed across a patient's entire life.
For drug developers, the challenge is to make the relevant benefit measurable and credible—early enough that the answers can shape the program, not merely decorate its launch materials.
Regulatory approval establishes an essential threshold. Thoughtful evidence planning can help establish why the asset deserves commercial value.